
STAT’s Pharmalittle: GLP-1s Become Lifestyle Drugs, Merck and Daiichi Withdraw Lung Cancer Application
A weekly roundup of health headlines: GLP-1 drugs shift from medicine to lifestyle, Merck and Daiichi pull back on cancer, and more.


A weekly roundup of health headlines: GLP-1 drugs shift from medicine to lifestyle, Merck and Daiichi pull back on cancer, and more.

Two cult classic stars race to hit SAG's $28,933 earnings mark to keep their health insurance. One begs for a SAG job.

A rare autism-linked genetic disorder may be far more common than thought, with thousands of cases undiagnosed.

FDA nominee Overton dodges senators' questions on abortion drug mifepristone, raising fears she'll cave to anti-abortion pressure.

STAT+ runs 'Up and down the ladder,' spotlighting Rakuten Medical's new CMO Hassan Danesi after one hire.

Two major trials show drugs can lower markers like lipoprotein(a) and IL-6 without changing patient outcomes. A moment of reckoning for preventive cardiology.

HHS chief RFK Jr. blocks states from ordering kid shots via CDC's VFC program, leaving millions of children without access.

Trump admin drops 760K Americans from ACA coverage, citing fraud. Critics fear real people lose coverage amid flawed administrative cleanup.

Trump admin to remove 760K ACA enrollees over fraud claims, saving $2.2B, as experts question the cuts' transparency.

Trump announces all 50 states join Medicaid's Most Favored Nation drug pricing model, saving billions on prescription drugs.

A Crystal Lake office collects mail for a lab named after a man no one can reach. Blue Cross Blue Shield pays, yet the patients remain in the dark.

House Dems plot to use oversight powers to grill Trump over drug pricing deals if they win back the House or Senate in November's midterms.
As an Amazon Associate, Clay Tribune earns from qualifying purchases.